These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of antiretroviral resistance on response in treatment-experienced patients. Kuritzkes DR AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S5-11. PubMed ID: 19967805 [TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. Molecular biological assessment methods and understanding the course of the HIV infection. Katzenstein TL APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050 [TBL] [Abstract][Full Text] [Related]
5. Attaining higher goals in HIV treatment: the central importance of adherence. Friedland GH; Williams A AIDS; 1999 Sep; 13 Suppl 1():S61-72. PubMed ID: 10546786 [TBL] [Abstract][Full Text] [Related]
6. Individualized therapy for the treatment-experienced patient. Walmsley S AIDS Read; 2003 Jun; 13(6 Suppl):S11-5. PubMed ID: 12838742 [TBL] [Abstract][Full Text] [Related]
7. Treatment interruption in HIV therapy: a SMART strategy? Jülg B; Goebel FD Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Garvie PA; Lensing S; Rai SN Pediatrics; 2007 Apr; 119(4):e893-9. PubMed ID: 17353298 [TBL] [Abstract][Full Text] [Related]
9. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
10. Predicting and monitoring antiretroviral adherence. Gross R LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853 [TBL] [Abstract][Full Text] [Related]
11. Investigational agents for salvage. Pozniak AL Curr Opin HIV AIDS; 2009 Nov; 4(6):524-30. PubMed ID: 20048721 [TBL] [Abstract][Full Text] [Related]
13. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF; Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392 [TBL] [Abstract][Full Text] [Related]
14. Management of patients with virologic and metabolic failure. Kuritzkes DR AIDS Read; 2003 Jun; 13(6 Suppl):S17-22. PubMed ID: 12838743 [TBL] [Abstract][Full Text] [Related]
15. [Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]. Llibre JM; Antela A; Arribas JR; Domingo P; Gatell JM; López-Aldeguer J; Lozano F; Miralles C; Moltó J; Moreno S; Ortega E; Riera M; Rivero A; Villalonga C; Clotet B Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):615-20. PubMed ID: 20888082 [TBL] [Abstract][Full Text] [Related]
16. What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1. Ruane PJ; Daar ES AIDS Read; 2004 Aug; 14(8):421-6, 431-2, 434. PubMed ID: 15338522 [TBL] [Abstract][Full Text] [Related]